The incidence of metabolic disorders such as obesity, type 2 diabetes and atherosclerosis has increased considerably in recent decades, and these diseases are some of the most serious threats to public health in the developed world. Chronic inflammation is a key feature of metabolic disorders. Many inflammatory mediators, such as tumornecrosis factor (TNF), interleukins and the cytokine-like proteins known as 'adipokines' , have been linked to the development of various forms of metabolic disorders 1,2 . Interleukin 1β (IL-1β) is a prominent proinflammatory cytokine, as it can efficiently cause the generation of other inflammatory mediators through signaling via IL-1 receptor, thus initiating a self-amplifying cytokine network 3 . Therefore, IL-1β is postulated to have an important role in the pathogenesis of metabolic disorders. Studies have tested the recombinant IL-1 receptor antagonist anakinra in the treatment of type 2 diabetes with some encouraging results 4 . Clinical trials also suggest that the noninflammasome cytokine TNF contributes to impaired glucose homeostasis and insulin resistance in patients with type 2 diabetes 5-7 . Therefore, both IL-1β and TNF could drive chronic inflammation in a cooperative manner, which highlights the importance of combined immunotherapy against multiple inflammatory cytokines. This review focuses on the role of the inflamamsome complex, which is important for the maturation of IL-1β in a variety of metabolic disorders. We also examine how metabolic alterations in cells, including the Warburg effect of aerobic glycolysis, contribute to inflammatory processes relevant for these diseases. Although most of the data are based on animal models, we underscore their potential translational relevance.
The incidence of metabolic disorders such as obesity, type 2 diabetes and atherosclerosis has increased considerably in recent decades, and these diseases are some of the most serious threats to public health in the developed world. Chronic inflammation is a key feature of metabolic disorders. Many inflammatory mediators, such as tumornecrosis factor (TNF), interleukins and the cytokine-like proteins known as 'adipokines' , have been linked to the development of various forms of metabolic disorders 1, 2 . Interleukin 1β (IL-1β) is a prominent proinflammatory cytokine, as it can efficiently cause the generation of other inflammatory mediators through signaling via IL-1 receptor, thus initiating a self-amplifying cytokine network 3 . Therefore, IL-1β is postulated to have an important role in the pathogenesis of metabolic disorders. Studies have tested the recombinant IL-1 receptor antagonist anakinra in the treatment of type 2 diabetes with some encouraging results 4 . Clinical trials also suggest that the noninflammasome cytokine TNF contributes to impaired glucose homeostasis and insulin resistance in patients with type 2 diabetes [5] [6] [7] . Therefore, both IL-1β and TNF could drive chronic inflammation in a cooperative manner, which highlights the importance of combined immunotherapy against multiple inflammatory cytokines. This review focuses on the role of the inflamamsome complex, which is important for the maturation of IL-1β in a variety of metabolic disorders. We also examine how metabolic alterations in cells, including the Warburg effect of aerobic glycolysis, contribute to inflammatory processes relevant for these diseases. Although most of the data are based on animal models, we underscore their potential translational relevance.
The inflammasome in diabetes and obesity
The inflammasome is a large multimeric danger-sensing platform that promotes autocatalytic activation of the cysteine protease caspase-1 and mediates the cleavage of inactive pro-IL-1β and IL-18, among other proteins, into their active forms 8, 9 . Several studies have provided evidence suggesting that the NLRP3 inflammasome has a critical role in the development of insulin resistance in mice with gene deletion [10] [11] [12] [13] [14] . In mice, genetic ablation of the cytoplasmic receptor NLRP3 (Nlrp3 −/− mice) or NLRP3 inflammasome-associated molecules such as the adaptor ASC (PYCARD; Pycard −/− mice) and caspase-1 (Casp1 −/− mice) leads to improved glucose tolerance and insulin sensitivity after mice are fed a high-fat diet (HFD); this links the NLRP3 inflammasome to insulin resistance. Several studies have explored how feeding mice a HFD might contribute to type 2 diabetes, as well as the role of inflammasome proteins. Ceramide, the specific product of the metabolism of long-chain saturated fatty acids, can cause activation of caspase-1 and the release of IL-1β in macrophages from wild-type mice but not those from Nlrp3 −/− mice 12 . The saturated free fatty acid palmitate induces the activation of caspase-1 and cleavage of IL-1β and IL-18 in an NLRP3-and ASC-dependent manner, but unsaturated free fatty acid does not 13 . Furthermore, palmitate signals through a pathway of AMP-activated kinase autophagy and mitochondrial reactive oxygen species (ROS) to activate the NLRP3 inflammasome. An NLRP3 inflammasome-dependent process affects insulin target tissues such as liver, muscle and adipose tissues (Fig. 1) . Therefore, such studies have explored the mechanisms of NLRP3 inflammasome A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation?
activation by danger-signaling molecules associated with the metabolism of saturated free fatty acids, and highlight the importance of NLRP3 inflammasome activation in the development of insulin resistance. Notably, a widely used therapeutic insulin secretagogue (glyburide) links insulin homeostasis and NLRP3 inflammasome activation. Glyburide can inhibit NLRP3 inflammasome-mediated caspase-1 activation and the release of both IL-18 and IL-1β 15 .
In addition to the essential role of the NLRP3 inflammasome and IL-1β in the impairment of insulin signaling in the insulin targets liver, muscle and adipose tissue, IL-1β also promotes beta-cell dysfunction and cell death directly 16 . Islet amyloid polypeptide (IAPP; also known as amylin) is a key inducer of NLRP3 inflammasome activation and IL-1β cleavage 17 . IAPP, a hormone secreted together with insulin, is deposited in the islet interstitium of patients with type 2 diabetes and is considered to represent a considerable risk factor for this disease 18 . IAPP forms amyloid structures, and amyloid particles activate the NLRP3 inflammasome 8 . Therefore, IAPP oligomers have been proposed to activate the NLRP3 inflammasome and IL-1β cleavage similarly to other crystalline activators of the NLRP3 inflammasome 17 . Other studies have suggested that high glucose concentrations induce beta-cell production and release of IL-1β in vitro, which then promotes functional impairment and apoptosis of beta cell in an autocrine manner 10, 19 . However, this effect seems to be specific to islets, as high concentrations of glucose do not promote IL-1β release induced by IAPP in bone marrow-derived dendritic cells. Instead, sufficient glucose is required for production of pro-IL-1β and IL-6 that is dependent on the transcription factor NF-κB but independent of the NLRP3 inflammasome 17 . The molecular mechanism that underlies glucose-induced release of IL-1β by islets remains to be determined and will be discussed below.
Another potential regulatory mechanism of inflammasome activation during obesity and insulin resistance is autophagy. Autophagy is a cell-intrinsic mechanism for the degradation and recycling of cellular components 20 . Variants of the human gene encoding the autophagyrelated protein ATG16L1 have been linked to Crohn's disease [21] [22] [23] [24] . Deletion of either Atg16l1 or Atg7 (which encode autophagy-related proteins) in mouse macrophages leads to more caspase-1 activation and IL-1β release than that in wild-type cells, but not more generation of TNF and IL-6. This has been observed in response to treatment with either lipopolysaccharide (LPS) alone or LPS in conjunction with NLRP3 inflammasome activators such as ATP and monosodium urate 25 . Such findings have been confirmed, and more detailed elucidation of molecular mechanisms involving disrupted mitochondrial homeostasis has been explored 13, 26, 27 . Inhibition of autophagy by gene deletion 18, 19 or palmitate treatment 13 leads to the accumulation of dysfunctional mitochondria and greater mitochondrial generation of ROS. Those events then activate the NLRP3 inflammasome. Leakage of mitochondrial DNA into the cytosol after autophagy inhibition has been suggested to coactivate inflammasomes 26 . Such studies have provided evidence that autophagy negatively regulates NLRP3 inflammasome activation by maintaining mitochondrial homeostasis. Accordingly, defective autophagy has been observed in mouse livers in obesity models of either genetic (ob/ob) or diet-induced (HFD) origin 28 . Although the mechanism by which an obese condition leads to defective autophagy has not been characterized, AMP-activated kinase and/or kinase mTOR signaling pathways may be potential upstream modulators, as these two evolutionally conserved signaling pathways can regulate autophagy by direct phosphorylation of ATG1 (refs. 29,30) . Therefore, defective autophagy associated with obesity and insulin resistance may promote inflammasome activation and amplify the inflammatory network in insulin target tissues.
In addition to the direct effect of the NLRP3 inflammasome on innate immunity, IL-1β and IL-18 have an essential role in shaping adaptive immune responses in several animal models, such as experimental autoimmune encephalomyelitis, arthritis and cytotoxic T cell-mediated antitumor responses 31 . Specifically, IL-1 promotes differentiation into the IL-17-producing helper T cell (T H 17 cell) lineage by upregulating IRF4 and RORγt, two essential transcription factors involved in T H 17 differentiation 32 , whereas IL-18, in synergy with IL-12, induces interferon-γ-producing type 1 helper T cells 33 . More importantly, the differentiation of human T H 17 cells requires IL-1β 34, 35 . As studies have suggested that the aberrant accumulation Figure 1 A model for the pathogenesis of type 2 diabetes involving adipose tissue, the pancreas and NLRP3. In adipose tissue, high concentrations of saturated free fatty acids such as palmitate lead to lower activity of AMPactivated kinase (AMPK), a central regulator of energy biosynthesis and lipid metabolism, which leads to defective autophagy of mitochondria ('mitophagy'). The accumulation of dysfunctional mitochondria then enhances mitochondrial generation of ROS and the release of mitochondrial DNA into the cytosol, both of which promote activation of the NLRP3 inflammasome and release of IL-1β (p17 subunit). A high concentration of glucose has been shown to promote the production of IL-1β by pancreatic beta cells but not by macrophages. The active IL-1β induces the activation of Jnk and IκB kinase through the IL-1 receptor (IL-1R), which impairs engagement of the insulin receptor (IR) by insulin receptor substrate 1 (IRS1) and the PI(3)K-kinase Akt signaling pathway. In the pancreas, the accumulation of IAPP activates the NLRP3 inflammasome and promotes the release IL-1β from macrophages, which causes beta-cell dysfunction and death. MAPK, mitogen-activated protein kinase; T2D, type 2 diabetes.
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and activation of lymphocytes (including both T cells and B cells) in adipose tissue impairs insulin sensitivity in obesity-induced insulin resistance [36] [37] [38] [39] [40] , activation of the NLRP3 inflammasome might lead to lymphocyte accumulation and activation in obesity and insulin resistance. Indeed, many fewer CD4 + and CD8 + effector memory T cells have been observed in the adipose tissue of Nlrp3 −/− mice fed a HFD than in similarly treated wild-type mice 12 , which suggested that the NLRP3 inflammasome-regulated adaptive immune response may also contribute to insulin resistance.
It has long been postulated that obesity is a strong risk factor for insulin resistance and type 2 diabetes, and this is partially mediated through enhancement of chronic inflammation in insulin target tissues 1 . The inflammasome has been proposed to affect adipocyte differentiation and HFD-induced obesity 11, 14 . Indeed, NLRP3-dependent activation of caspase-1 and IL-1β inhibits adipocyte differentiation and insulin signaling 11 . Furthermore, genetic ablation of the NLRP3 inflammasome or pharmacological inhibition of caspase-1 provides a beneficial effect in HFD-induced obesity, presumably by leading to greater energy expenditure 14 . However, the protective role of the NLRP3 inflammasome in HFD-induced obesity has not been uniformly observed, as two other studies have not confirmed those findings 12, 13 . Those two studies did not show a difference between Nlrp3 −/− mice and wild-type mice in total body weight after feeding of a HFD 12, 13 , although NLRP3 seems to have a role in adipocyte morphology 12 . The reason for the different observations is unknown but may involve subtle differences such as HFD from different sources. Another potential link to obesity is indicated by the greater β-oxidation of fatty acids in Casp1 −/− mice than in wild-type mice. This is probably due to lower IL-1β, as IL-1β limits β-oxidation and will therefore lead to less adiposity. Accordingly, treatment of obese mice with a caspase-1 inhibitor leads to higher fat oxidation rates 11 . NLRP3 inflammasome activation might therefore promote obesity.
The inflammasome in atherosclerosis
Atherosclerosis has components of a chronic inflammatory disease characterized by the accumulation of lipid components and recruitment of cells of the immune response to atherosclerotic lesions 41, 42 . When low-density lipoprotein, a cholesterol-containing lipoprotein, is retained in the artery wall, it leads to vascular inflammation and accumulation of cholesterol, partially as cholesterol crystals 41, 42 . Among inflammatory mediators, IL-1β has an important role in promoting the development of lipid plaques and destabilizing the plaques in mice. In mice deficient in apolipoprotein E (Apoe −/− mice) that spontaneously develop atherosclerosis because of hypercholesterolemia, IL-1β deficiency leads to attenuated development of atherosclerotic lesions 43 . Treatment with an antagonist of the IL-1 receptor prevents lesion development 44 . Therefore, experimental animal studies support the idea that IL-1β acts together with other proinflammatory cytokines such as TNF to exacerbate the pathology of metabolic disorders. The role of inflammatory cytokine IL-6 in obesity and insulin resistance remains controversial. Although IL-6 has been proposed to have a detrimental role in impairing glucose homeostasis and insulin sensitivity 45 , another study has suggested that IL-6 has a beneficial effect by promoting insulin secretion and maintaining of glucose homeostasis in diet-induced or genetic animal models 46 .
Cholesterol crystals activate the NLRP3 inflammasome and release of IL-1β in mouse and human macrophages, which indicates that the NLRP3 inflammasome may have a role in atherosclerosis 47, 48 . The accumulation of a small amount of cholesterol crystals has been observed in early diet-induced atherosclerotic lesions and has been associated with the recruitment of inflammatory macrophages 47 . Cholesterol crystals generated in vitro activate caspase-1 and the cleavage of both IL-1β and IL-18 in LPS-primed human peripheral blood mononuclear cells and mouse macrophages; both events depend on NLRP3 and ASC 47, 48 . Moreover, cholesterol crystal-induced activation of the NLRP3 inflammasome is sensitive to treatment with cytochalasin D or bafilomycin, which suggests that phagocytosis and lysosome acidification are required for inflammasome activation. This is consistent with the induction of NLRP3 inflammasome activation by other crystals, such as monosodium urate, silica, asbestos and alum [49] [50] [51] [52] . In agreement with the in vitro data, hypercholesterolemic mice deficient in the receptor for low-density lipoprotein (Ldlr −/− ) that are reconstituted with bone marrow from Nlrp3 −/− , Pycard −/− or Il1b −/− mice develop many fewer atherosclerotic plaques than do those reconstituted with wild-type bone marrow 30 . Such findings suggest critical roles for hematopoietic cell-derived NLRP3, ASC and IL-1β in the development of atherosclerotic lesions. However, the crucial role of the NLRP3 inflammasome in atherosclerosis has been challenged by another study of double-mutant mice generated by crossing Apoe −/− mice with Nlrp3 −/− , Pycard −/− or Casp1 −/− mice 53 . That study did not find any differences in atherosclerosis progression, infiltration of plaques by macrophages or plaque stability with or without the NLPR3 inflammasome. The difference between those two studies 30, 53 is the investigation of a hematopoietic cell-derived NLRP3 inflammasome versus a whole body-derived NLRP3 inflammasome in the development of atherosclerosis. The NLRP3 inflammasome may also function in the stromal compartment to regulate disease progression in addition to functioning the hematopoietic compartment, especially in colitis and colitis-associated cancer 54, 55 . Therefore, further investigations are needed to clarify these differences.
The inflammasome in gout
Gout is historically known as a 'disease of kings' as it is thought to result from a rich diet, particularly one high in purines. It is associated with high concentrations of uric acid (hyperuricemia) in the blood; this uric acid forms crystals that are deposited in the joints. Uric acid can be released from dying cells, activating cells as a danger signal 56 . IL-1β has an important role in the promotion of inflammatory responses in joints, as has been supported by several clinical trials in which the treatment of gout with anakinra or other drugs that inhibit IL-1β has ameliorated symptoms [57] [58] [59] [60] .
The mechanisms by which urate crystals cause inflammatory arthritis and IL-1β is generated remained largely unknown until the NLRP3 inflammasome was identified as the link between urate crystals and gout 49 . Monosodium urate and calcium pyrophosphate dihydrate induce cleavage of caspase-1, and IL-1β or IL-18 in LPSprimed macrophages that depends on NLRP3 and ASC. In vivo, NLRP3 inflammasome-mediated generation of IL-1β promotes neutrophil recruitment and peritoneal inflammation induced by monosodium urate. However, the mechanism whereby monosodium urate or other crystal structures activate the NLRP3 inflammasome is unclear. Unlike what is known about other germline-encoded pathogen-recognition receptors, there is no evidence to suggest direct recognition of danger signals by NLRP3. Therefore, the NLRP3 inflammasome may detect some form of alteration in cellular homeostasis induced by danger signals. One such proposed signal has been an increase in the generation of ROS 8 . One study has suggested that thioredoxin-interacting protein, a protein upregulated by glucose and linked to insulin resistance, interacts with NLRP3, leading to IL-1β release 10 . Inflammasome activators induce the transfer of thioredoxin-interacting protein from thioredoxin to NLRP3 in a process that involves ROS. However, that finding has been npg challenged, particularly in macrophages, by another study 17 . Caspase-1-interacting proteins, including the adaptors cIAP1, cIAP2 and TRAF2, are also required for spontaneous and agonist-induced cleavage of caspase-1 (ref. 61 ). The E3 ligase activity of cIAP mediates Lys63-linked polyubiquitination of caspase-1, although its functional relevance to caspase-1 maturation remains to be explored. Other potential mechanisms of inflammasome activation involve the participation of additional effector molecules such as other Nod-like receptors (NLRs) or pathogen-recognition receptors such as Toll-like receptors (TLRs) and cytosolic receptor RIG-I-like receptors. For example, proteins of the NAIP (NLR apoptosis-inhibitory protein) family mediate activation of the NLRC4 inflammasome through a direct ligand-binding mechanism 62 . Prokaryotic mRNA promotes activation of the NLRP3 inflammasome via TRIF, an adaptor downstream of TLR3 and TLR4 (ref. 63) . RNA virus-induced activation of RIG-I signaling leads to inflammasome activation 64 . Early studies noted the transcriptional induction of NLRP3 by microbes 65, 66 , whereas a subsequent study has suggested that ROS induce NLRP3 expression 67 . Hence, transcriptional effects on components of the inflammasome, in addition to post-translational effects, must be taken into consideration.
Although it has been well documented that crystal structures such as monosodium urate, silica, asbestos and alum induce NLRP3 inflammasome-dependent cleavage of caspase-1 and IL-1β or IL-18, particularly in vitro [49] [50] [51] [52] , studies have shown NLRP3 inflammasomeindependent effects of uric acid, silica and alum in the development of T helper type 2 (T H 2) immune responses and T H 2 cell-associated immunoglobulin E responses 68, 69 . For example, uric acid is released in the airways of asthmatic patients and allergen-challenged mice and promotes T H 2 cell immune responses by activating dendritic cells through signaling pathways of the kinases Syk and PI(3)Kδ 54 . Other studies have reported that silica and alum promote the production of prostaglandin E 2 in macrophages through the Syk-kinase p38 pathway, which enhances the production of immunoglobulin E associated with T H 2 cell responses 68, 69 . Both of these studies have found that NLRP3 has no effect 68, 69 . Therefore, crystals (including alum adjuvant) induce both NLRP3 inflammasome-dependent and NLRP3 inflammasome-independent immune effects. Further investigation is warranted to clarify the role of the inflamamsome in these responses in physiological settings.
Metabolic changes in inflammatory signaling
Another emerging aspect of IL-1β is the role of glucose metabolism in transcription of the gene encoding IL-1β. As mentioned above, glucose boosts the production of IL-1β in pancreatic beta cells, although no mechanism has been identified for this 19 . This is less evident in macrophages, in which although glucose is required, high (millimolar) concentrations of glucose do not boost the response. However, treating macrophages with 2-deoxyglucose inhibits transcription of the gene encoding IL-1β induced by LPS but does not affect transcription of the gene encoding TNF 17 . Moreover, 2-deoxyglucose inhibits glycolysis by acting as a competitive substrate for hexokinase, thereby limiting glucose metabolism. Why would this affect transcription of the gene encoding IL-1β?
LPS profoundly affects the metabolic profile of target cells. In dendritic cells, LPS promotes aerobic glycolysis, a process called the 'Warburg effect' 70, 71 . Warburg originally defined this process in tumor cells, whereby respiration and the Krebs cycle (the tricarboxylic acid cycle) in mitochondria is limited and glycolysis is enhanced. Several reasons for this metabolic shift have been proposed, notably, more ATP production to meet the energy demands of the tumor cells. Glycolysis, although it is less able to generate ATP, can be greatly enhanced through induction of the enzymes involved 72 . A second reason is biosynthesis, as intermediates for biosynthesis of amino acids, lipids and nucleotides are made by glycolysis 73 . This could be a mechanism for the enhanced production of uric acid in inflammation, in the case of the pentose phosphate pathway. The mechanism of the Warburg effect in tumors involves induction of the embryonic pyruvate kinase M2 isoform 74 , which strongly promotes induction of hypoxia-inducible factor 1α (HIF-1α) 75 . Pyruvate kinase M2 is present in a complex with HIF-1α and prolyl hydroxylase 3 (PHD3) on the promoter of the gene encoding HIF-1α. HIF-1α induces glycolytic enzymes, promoting the glycolytic flux 76 . This same process could happen in response to LPS, as LPS stabilizes HIF-1α through a poorly defined mechanism, and HIF-1α-deficient (Hif1a −/− ) macrophages are defective in their response to LPS 77 . LPS also induces the ubiquitous isoform of uPFK2 (6-phosphofructo-2-kinase-fructose-2,6-bisphosphatase), which strongly promotes glycolysis 78 . Attenuation of uPFK2 thus limits macrophage responses to LPS 78 . Another mechanism might involve lower expression of PHD2 and Figure 2 Metabolic fluxes, NLRP3 and IL-1β. Hyperlipidemia, in the form of saturated fatty acids such as palmitate, activates the NLRP3 inflammasome, which leads to the activation of caspase-1 and processing of pro-IL-1β. Impaired mitochondrial metabolism, including lower β-oxidation of fatty acids, could promote this process, as does the production of ROS. Activation of TLR4 by LPS or minimally modified oxidized low-density lipoprotein (mmLDL) promotes glycolysis through the induction of enzymes such as uPFK2, which leads to enhanced ATP production and nucleotide biosynthesis through the pentose phosphate pathway. Purines, including uric acid, could be overproduced through this process, leading to activation of the NLRP3 inflammasome. IL-1β gives rise to insulin resistance, causing enhanced IAPP production, which in turn further activates NLRP3. Insulin resistance in liver and muscle might spare glucose for macrophages. TCA, tricarboxylic acid. The signal provided by glycolysis for the responses outlined above is unknown but could also involve a signal from mitochondria, as LPS affects mitochondrial metabolism. LPS can limit mitochondrial metabolism and oxidative phosphorylation, although the mechanism is unknown 80 . There is lower expression of genes encoding various proteins involved in mitochondrial function in LPS-treated cells than in untreated cells 27 . This could lead to the buildup of intermediates such as succinate, a known inhibitor of PHD2, the enzyme that hydroxylates HIF-1α, leading to degradation of HIF-1α 81 . Succinate would therefore lead to higher HIF-1α concentrations. Also, a buildup of ROS in response to LPS may be involved in the induction of HIF-1α 82 . It has been shown that 2-deoxyglucose can lower the production of ROS and succinate, which provides a possible explanation for how it blocks induction of IL-1β by LPS 83 . The ATP produced by glycolysis is required for maintenance of the mitochondrial membrane potential in the face of mitochondrial shutdown 84 .
Therefore, LPS signaling through TLR4 involves an alteration in intracellular metabolism that determines LPS responses. The shift to aerobic glycolysis is required for the induction of IL-1β mRNA. The inflammasome is activated by hyperlipidemia, which leads to more IL-1β production. IL-1β then causes insulin resistance and less oxidation of fatty acids in the mitochondria. These events promote obesity, which produces a 'vicious cycle' that is further enhanced by more IAPP production in the pancreas, with IAPP being synthesized in concert with insulin and forming amyloid. IAPP promotes further IL-1β production, which ultimately is toxic to beta cells in the pancreas. However, although a causal link between IAPP and the pathogenesis of type 2 diabetes is intriguing as a hypothesis, it has yet to be proven. A similar scenario could occur in atherosclerosis, in which cholesterol crystals exacerbate the inflammatory process through NLRP3, with this process promoting plaque formation. TLR4 could be a key driver in these events, as it responds to fatty acids and also to minimally oxidized low-density lipoprotein, providing pro-IL-1β and priming the inflammasome. The shift to the Warburg effect could therefore determine the process of inflammation (Fig. 2) .
Another example of the importance of the Warburg effect in inflammation has been provided by a study of T H 17 cells. In this study, HIF-1α enhances T H 17 development through activation of RORγt and recruitment of the histone acetyltransferase p300 to the promoter of the gene encoding IL-17 (ref. 85) . HIF-1α also attenuates the development of regulatory T cells by binding to their lineage-specifying transcription factor Foxp3 and targeting it for proteasomal degradation. Hif1a −/− mice do not generate T H 17 cells and are resistant to experimental autoimmune encephalitis 85 . Another study has obtained similar results and, notably, HIF-1α−dependent glycolysis acts as a metabolic checkpoint for the differentiation of T H 17 cells 86 . Notably, 2-deoxyglucose converts a T H 17 cell into a regulatory T cell 86 . Because T H 17 cells are more proinflammatory than regulatory T cells, this further emphasizes how the Warburg effect determines inflammation, as it is important both for inflammatory cytokine production from macrophages and dendritic cells and for the generation of T H 17 cells.
Why would IL-1β cause insulin resistance? There are two possible options. Insulin resistance occurs mainly in liver and smooth muscle cells and is thought to involve induction of the inhibitors SOCS2 and SOCS3 (ref. 87 ) and activation of the kinase Jnk and IκB kinase 88 to limit insulin signaling. This could spare glucose for macrophages, which require glucose for energy demands and biosynthesis, both of which involve a switch to aerobic glycolysis, probably through HIF-1α (Fig. 2) . A second possibility is limiting glucose uptake in a negative feedback loop, as this could impair further IL-1β transcription and would also limit the production of ROS from mitochondria. In type 2 diabetes, however, the ongoing induction of IL-1β in response to the various stimuli, including IAPP, suggests that any negative feedback effect is overwhelmed and IL-1β then becomes pathogenic.
Conclusions
As noted above, much evidence suggests an intimate relationship among IL-1β, the NLRP3 inflammasome and the metabolism of lipids and carbohydrates. This occurs at the level of enhanced NLRP3 inflammasome activation and processing of IL-1β to the mature cytokine in response to saturated fatty acids and also at the level of glucose metabolism through the requirement of glycolysis for induction of IL-1β mRNA. Glycolysis and HIF-1α are key for T H 17 differentiation. The pathogenic role of IL-1β in plaque formation in atherosclerosis and in insulin resistance and beta−cell loss in type 2 diabetes attests to the importance of these processes in these metabolic diseases. The exacerbation of NLRP3 inflammasome activation by cholesterol crystals in atherosclerosis, and by IAPP in type 2 diabetes, provides a positive feedback loop to promote disease pathogenesis. Uric acid crystals, another consequence of metabolic disorders, are also NLRP3 inflammasome activators that lead to IL-1β production in gout. Insight into the molecular basis of these diseases could help in the design of new therapies.
